WallStSmart

Heron Therapeuti (HRTX)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 43934% more annual revenue ($66.57B vs $151.18M). MRK leads profitability with a 4.8% profit margin vs -22.5%. MRK earns a higher WallStSmart Score of 36/100 (F).

HRTX

Avoid

29

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -9.57

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HRTX.

MRKSignificantly Overvalued (-74.5%)

Margin of Safety

-74.5%

Fair Value

$83.26

Current Price

$144.31

$61.05 premium

UndervaluedFair: $83.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HRTX0 strengths · Avg: 0/10

No standout strengths identified

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$365.34B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

HRTX4 concerns · Avg: 3.8/10
Price/BookValuation
11.9x4/10

Trading at 11.9x book value

Revenue GrowthGrowth
1.3%4/10

1.3% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$55.85M3/10

Smaller company, higher risk/reward

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : HRTX

HRTX has a balanced fundamental profile.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : HRTX

The primary concerns for HRTX are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 21.48 is elevated, increasing financial risk.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

HRTX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

HRTX carries more volatility with a beta of 1.61 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Heron Therapeuti

HEALTHCARE · BIOTECHNOLOGY · USA

Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?